First and only FDA-approved device of its kind demonstrates consistently high rates of target limb salvage and freedom from clinically-driven target lesion revascularization
Acceptance based on results from the phase 3 KEYNOTE-091 trial
Cantourage introduces second Clever Leaves medical cannabis product to the German market
Doubling of median overall survival seen in QuANTUM-First results presented at EHA Presidential Symposium
Strides was granted a Competitive Generic Therapy (CGT) designation for its ANDA.
The production and supply in Canada are designed to address the growing need for no-carrier-added Lutetium-177 (n.c.a. Lu-177) in North America
Centre of Excellence at Kharel comprises Skill-building Centre and Primary, Secondary and Higher Secondary schools
TAK-003 is currently undergoing regulatory review for potential licensure in both the European Union
New milestone in the establishment of super-trillion antibody libraries for antibody discovery of challenging targets
New Director supports NASDAQ rule on diversity
Subscribe To Our Newsletter & Stay Updated
